News for 'SFE' - (Clarient Enters into Training and Consulting Agreement with
University of Pennsylvania School of Medicine)
ALISO VIEJO, Calif., Sep 29, 2008 (BUSINESS WIRE) -- Clarient, Inc.
(NASDAQ:CLRT), a premier anatomic pathology and molecular testing services
resource for pathologists, oncologists and the pharmaceutical industry,
announced today that it has entered into an agreement with the University of
Pennsylvania School of Medicine's Flow Cytometry and Cell Sorting Resource
Laboratory (Flow Cytometry Lab) for a multilevel educational and technical
training program. This innovative program is intended to provide the technical
and professional staff at Clarient with the necessary skills to provide superior
clinical service using both standard and non-standard assays.
"We are delighted to enter into this revolutionary and invaluable educational
collaboration with the Flow Cytometry Lab at UPenn," commented Michael Pellini,
M.D., President and Chief Operating Officer of Clarient. "Their expertise will
enable Clarient's team to stay at the forefront of flow cytometry technology and
practices. Based in one of the nation's premiere pathology and laboratory
medicine departments, the Flow Cytometry Lab will help Clarient bring the
highest level of clinical services to our clients."
The agreement offers quarterly on-site training by Flow Cytometry Lab personnel,
which will include evaluating current procedures and education in specific
routine processes, guidelines for clinical evaluation of hematologic
malignancies, quality control and quality assurance procedures, and the
development of programs to assure compliance with the State of California and
the College of American Pathologists educational and professional requirements.
In addition, Flow Cytometry Lab professionals will provide on demand consulting
and technical guidance regarding equipment and educational and process issues,
and will host an annual seminar on current technological topics of interest.
The University of Pennsylvania School of Medicine's Pathology Department, which
includes The Flow Cytometry and Cell Sorting Resource Laboratory, ranks first in
funding from the National Institutes of Health for pathology-related grants, and
is considered one of the leading academic departments of pathology in the U.S.
About Clarient
Clarient combines innovative technologies with world-class expertise to assess
and characterize cancer. Clarient's mission is to provide the services,
resources and critical information to improve the quality and reduce the cost of
patient care, and accelerate the drug development process. The Company's
principal customers include pathologists, oncologists, hospitals and
biopharmaceutical companies. The rise of individualized medicine as the new
direction in oncology has created the need for a centralized resource providing
leading diagnostic technologies such as flow cytometry and molecular testing.
Clarient is that resource, having created a state-of-the-art commercial cancer
laboratory providing the most advanced oncology testing and drug development
services available both onsite and over the web. Clarient is a Safeguard
Scientifics partner company. www.clarientinc.com.
About Safeguard Scientifics
Founded in 1953 and based in Wayne, Penn., Safeguard Scientifics, Inc.
(NYSE:SFE) provides growth capital for entrepreneurial and innovative technology
and life sciences companies. Safeguard targets technology companies in Software
as a Service (SaaS) / Internet-based Businesses, Technology-Enabled Services and
Vertical Software Solutions, and life sciences companies in Molecular and
Point-of-Care Diagnostics, Medical Devices and Specialty Pharmaceuticals with
capital requirements between $5 million and $50 million. Safeguard participates
in expansion financings, corporate spin-outs, management buyouts,
recapitalizations, industry consolidations and early-stage financings.
www.safeguard.com.
PINKY RHYMES WITH STINKY!
